Personalised home hazard assessments and interventions will help to prevent older and at-risk people from suffering from falls, according to new NICE guideline ...

There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The highly specialised technologies evaluation committee is a standing advisory committee of NICE. Committee members are asked to declare any interests in the technology being evaluated. If it is ...

Tools to help you put the guidance into practice.

Leniolisib (Joenja) is available on the NHS as a possible treatment for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over. Is this treatment right for me? Your healthcare ...

Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.

Leniolisib is recommended, within its marketing authorisation, for treating activated phosphoinositide 3‑kinase delta syndrome (APDS) in people 12 years and over. Leniolisib is recommended only if the ...

Leniolisib (Joenja, Pharming) is indicated for 'the treatment of activated phosphoinositide 3‑kinase delta (PI3Kδ) syndrome (APDS) in adult and paediatric patients 12 years of age and older'. The ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...